search
Back to results

Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of MAM.

Primary Purpose

Malnutrition

Status
Completed
Phase
Not Applicable
Locations
Malawi
Study Type
Interventional
Intervention
C-RUSF
HIPRO RUSF
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malnutrition focused on measuring Moderate Acute Malnutrition, Malnutrition

Eligibility Criteria

6 Months - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • MUAC < 12.5 cm and ≥ 11.5 cm
  • without bipedal edema

Exclusion Criteria:

  • simultaneously involved in another research trial or supplemental feeding program
  • developmentally delayed, have a chronic debilitating illness such as cerebral palsy
  • history of peanut or milk allergy

Sites / Locations

  • Local Feeding Clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

C-RUSF

HIPRO RUSF

Arm Description

Control/Standard RUSF

New RUSF product

Outcomes

Primary Outcome Measures

Recovery from Moderate Acute Malnutrition using Mid-Upper Arm Circumference (MUAC) and Weight for Height Z score (WHZ)
Number of participants achieving a Mid-Upper Arm Circumference (MUAC) ≥ 12.5 cm and/or WHZ>-2 within a 12 week treatment period

Secondary Outcome Measures

Full Information

First Posted
May 18, 2018
Last Updated
March 12, 2020
Sponsor
Washington University School of Medicine
Collaborators
Arla Foods, Kamuzu University of Health Sciences, Project Peanut Butter
search

1. Study Identification

Unique Protocol Identification Number
NCT03549156
Brief Title
Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of MAM.
Official Title
Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomised, Investigator-blinded, Clinical Effectiveness Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
June 25, 2018 (Actual)
Primary Completion Date
March 8, 2019 (Actual)
Study Completion Date
March 8, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
Arla Foods, Kamuzu University of Health Sciences, Project Peanut Butter

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, randomised, double-blinded, controlled clinical effectiveness trial of two supplementary foods in the treatment of MAM. The setting will be 21 rural sites in southern Malawi. The participants will be 1800 children 6-59 months old with MAM, defined as mid-upper arm circumference (MUAC) ≥ 11.5 cm and < 12.5 cm and/or a weight-for-height Z-score (WHZ) between -2 and -3 without bipedal edema. Children will receive approximately 75 kcal/kg/d (314 kJ/kg/d) of one of two RUSFs in two-week rations for outpatient therapy of MAM. The two supplements will be a novel, locally produced peanut/dairy RUSFs, one with a high protein quality (HIPRO RUSF) or one with a standard protein quality, referred to as control RUSF (C-RUSF). The primary outcome measures will be recovery from MAM (achieving MUAC ≥ 12.5 cm and/or WHZ>-2 by 12 weeks) or failure (death, development of severe acute malnutrition, transfer to hospital for inpatient care, failure to recover from MAM by 12 weeks, default). Secondary outcome measures include rates of weight, height, and mid-upper-arm circumference (MUAC) gain, time to graduation, and adverse effects from the supplementary foods.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malnutrition
Keywords
Moderate Acute Malnutrition, Malnutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Each food will be randomized to two colors with the study coordinator, nurse, caregivers blinded to the which color is which food.
Allocation
Randomized
Enrollment
1858 (Actual)

8. Arms, Groups, and Interventions

Arm Title
C-RUSF
Arm Type
Active Comparator
Arm Description
Control/Standard RUSF
Arm Title
HIPRO RUSF
Arm Type
Active Comparator
Arm Description
New RUSF product
Intervention Type
Dietary Supplement
Intervention Name(s)
C-RUSF
Other Intervention Name(s)
Ready-to-use supplementary food
Intervention Description
-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
Intervention Type
Dietary Supplement
Intervention Name(s)
HIPRO RUSF
Other Intervention Name(s)
Ready-to-use supplementary food
Intervention Description
HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
Primary Outcome Measure Information:
Title
Recovery from Moderate Acute Malnutrition using Mid-Upper Arm Circumference (MUAC) and Weight for Height Z score (WHZ)
Description
Number of participants achieving a Mid-Upper Arm Circumference (MUAC) ≥ 12.5 cm and/or WHZ>-2 within a 12 week treatment period
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: MUAC < 12.5 cm and ≥ 11.5 cm without bipedal edema Exclusion Criteria: simultaneously involved in another research trial or supplemental feeding program developmentally delayed, have a chronic debilitating illness such as cerebral palsy history of peanut or milk allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Manary, MD
Organizational Affiliation
Washington University School of Medicine in St. Louis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Local Feeding Clinics
City
Blantyre
Country
Malawi

12. IPD Sharing Statement

Learn more about this trial

Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of MAM.

We'll reach out to this number within 24 hrs